News about "BESREMi "

PharmaEssentia Secures Taiwan Approval for BESREMi in Essential Thrombocythemia

PharmaEssentia Secures Taiwan Approval for BESREMi in Essential Thrombocythemia

PharmaEssentia has received Taiwan approval for BESREMi as the first globally approved treatment for Essential Thrombocythemia (ET), marking the first new approved therapy for the disease in nearly 30 years.

BESREMi | 11/06/2026 | By News Bureau 100

Pint Pharma Gets ANVISA Approval of BESREMi for Polycythemia Vera

Pint Pharma Gets ANVISA Approval of BESREMi for Polycythemia Vera

Polycythemia Vera (PV) is a rare, chronic, debilitating, and potentially fatal myeloproliferative neoplasm, originating from a disease-initiating stem cell in the bone marrow.

BESREMi | 21/03/2025 | By Aishwarya 587


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members